查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595054

组织工程皮肤替代品的全球市场

Tissue Engineered Skin Substitutes
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 89 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球组织工程皮肤替代品市场将达到 54 亿美元

组织工程皮肤替代品的全球市场预计 2023 年为 31 亿美元，预计到 2030 年将达到 54 亿美元，2023-2030 年分析期间复合年增长率为 8.2%。生物替代品是本报告分析的细分市场之一，预计复合年增长率为 8.8%，到分析期结束时将达到 29 亿美元。分析期间，合成替代品领域的复合年增长率预计为 8.0%。

美国市场预估8.53亿美元，中国预期复合年增长率7.6%

到 2023 年，美国组织工程皮肤替代品市场预计将达到 8.53 亿美元。中国作为全球第二大经济体，预计2030年市场规模将达8.225亿美元，2023年至2030年复合年增长率为7.6%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 7.6% 和 6.6%。在欧洲，德国的复合年增长率预计约为 6.5%。

全球组织工程皮肤替代品市场 - 主要趋势和驱动因素总结

组织工程皮肤替代品如何彻底改变创伤护理？

组织工程皮肤替代品是先进的生物材料，旨在取代遭受严重烧烫伤、慢性伤口和其他皮肤损伤的患者受损或流失的皮肤组织。这些替代品是使用生物相容性支架、细胞和生长因子开发的，以模仿天然皮肤的结构和功能，促进更快的癒合并减少疤痕。组织工程皮肤替代品可作为同种异体移植物、自体移植物和异质骨移植，为重组手术、皮肤科和伤口处理提供重要的解决方案。随着医疗保健系统专注于改善患者的治疗效果和加快康復速度，组织工程皮肤替代品作为传统皮肤移植的有效替代品正在取得进展。

组织工程皮肤替代品市场的关键部分是什么？

主要产品类型包括细胞替代品、细胞替代品、复合替代品。细胞替代品主要由胶原蛋白等生物材料製成，广泛应用于烧伤治疗和慢性伤口管理，占有很大份额。含有活细胞的细胞替代品由于能够与患者皮肤融合併促进癒合而越来越受欢迎。组织工程皮肤替代品的应用包括烧伤管理、糖尿病溃疡、压疮和重组手术，其中烧伤管理占最大部分，因为严重情况下皮肤修復至关重要。组织工程皮肤替代品的最终使用者包括医院、伤口护理中心和专科诊所。医院在市场中处于领先地位，将这些替代品用于烧伤治疗、重组手术、慢性伤口管理以及其他需要快速癒合和缩短住院时间的情况。伤口护理中心使用皮肤替代来治疗糖尿病溃疡、褥疮和其他不癒合伤口，以改善患者康復并降低感染风险。此外，专业诊所在整容和重组手术中使用这些替代品，以实现更好的美容效果和更短的恢復时间。

组织工程皮肤替代品如何应用于医疗保健？

在医院，组织工程皮肤替代品用于治疗严重烧烫伤、深度伤口和手术后恢復，以促进更快的癒合并最大限度地减少疤痕形成。在伤口护理中心，这些替代品在糖尿病溃疡和褥疮等慢性伤口的治疗中发挥着重要作用，有助于皮肤组织再生和预防感染疾病。在重组和整容手术中，皮肤替代品可以恢復美观并改善皮肤功能，特别是在创伤、先天性缺陷和癌症手术的情况下。此外，在这些皮肤替代中使用先进的生物材料可以减少对捐赠者皮肤移植的需求，从而最大限度地减少併发症和恢復时间。

推动组织工程皮肤替代品市场成长的因素有哪些？

组织工程皮肤替代品市场的成长受到多种因素的推动，包括烧伤和慢性伤口盛行率的上升、组织工程的进步以及对更好的创伤护理解决方案的需求不断增加。生物工程支架、注入生长因子的替代品以及改进与自然组织的整合等创新正在扩大整个医疗保健领域的应用。组织工程皮肤替代品专注于改善患者的治疗效果、缩短復原时间并最大限度地减少住院时间，为伤口管理提供了重要的好处，进一步推动了需求。此外，医疗保健支出的增加、对先进伤口护理的认识不断提高以及对再生医学的投资不断增加，都有助于市场成长并推动组织工程皮肤替代品在各种医疗环境中的采用。

部分

产品（生物、合成、生物合成）；最终用途（急性、慢性）；最终使用者（医院、伤口护理中心、其他最终使用者）

受访企业范例（33家知名企业）

  • Amarantus Bioscience Holdings, Inc.
  • BSN medical
  • ConvaTec Group PLC
  • Integra LifeSciences Corporation
  • Kerecis
  • LifeNet Health
  • Mallinckrodt
  • Medline Industries, Inc.
  • MiMedx
  • Molnlycke Health Care AB
  • Organogenesis Inc.
  • Regenicin
  • Smith & Nephew
  • Tissue Regenix

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他领域

第四章 比赛

简介目录
Product Code: MCP22954

Global Tissue Engineered Skin Substitutes Market to Reach US$5.4 Billion by 2030

The global market for Tissue Engineered Skin Substitutes estimated at US$3.1 Billion in the year 2023, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2023-2030. Biological Substitutes, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Synthetic Substitutes segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$853.0 Million While China is Forecast to Grow at 7.6% CAGR

The Tissue Engineered Skin Substitutes market in the U.S. is estimated at US$853.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$822.5 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.6% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Tissue Engineered Skin Substitutes Market - Key Trends and Drivers Summarized

How Are Tissue Engineered Skin Substitutes Revolutionizing Wound Care?

Tissue engineered skin substitutes are advanced biomaterials designed to replace damaged or lost skin tissues in patients suffering from severe burns, chronic wounds, and other skin injuries. These substitutes are developed using biocompatible scaffolds, cells, and growth factors to mimic the structure and function of natural skin, promoting faster healing and reducing scarring. Available as allogeneic, autologous, and xenogeneic grafts, tissue engineered skin substitutes provide vital solutions in reconstructive surgery, dermatology, and wound management. As healthcare systems emphasize better patient outcomes and faster recovery, tissue engineered skin substitutes have gained traction as effective alternatives to traditional skin grafts.

What Are the Key Segments in the Tissue Engineered Skin Substitutes Market?

Major product types include acellular, cellular, and composite substitutes. Acellular substitutes, made primarily from collagen or other biomaterials, hold a significant share due to their wide use in burn treatments and chronic wound management. Cellular substitutes, which contain living cells, are gaining popularity for their ability to integrate with the patient’s skin and enhance healing. Applications of tissue engineered skin substitutes cover burn management, diabetic ulcers, pressure ulcers, and reconstructive surgeries, with burn management representing the largest segment due to the critical need for rapid skin regeneration in severe cases. End-users of tissue engineered skin substitutes include hospitals, wound care centers, and specialty clinics. Hospitals lead the market, utilizing these substitutes for burn treatments, reconstructive surgeries, and chronic wound management, where rapid healing and reduced hospitalization are critical. Wound care centers use skin substitutes for treating diabetic ulcers, pressure sores, and other non-healing wounds, improving patient recovery and reducing the risk of infection. Additionally, specialty clinics employ these substitutes in cosmetic and reconstructive surgeries, ensuring better aesthetic outcomes and faster recovery times.

How Are Tissue Engineered Skin Substitutes Applied in Healthcare?

In hospitals, tissue engineered skin substitutes are used to treat severe burns, deep wounds, and post-surgical recovery, promoting faster healing and minimizing scar formation. In wound care centers, these substitutes play a critical role in managing chronic wounds like diabetic ulcers and pressure sores, where they help regenerate skin tissues and prevent infections. In reconstructive and cosmetic surgeries, skin substitutes provide aesthetic restoration and improved skin function, particularly in cases of trauma, congenital defects, and post-cancer surgeries. The use of advanced biomaterials in these substitutes also reduces the need for donor skin grafts, minimizing complications and recovery times.

What Factors Are Driving the Growth in the Tissue Engineered Skin Substitutes Market?

The growth in the Tissue Engineered Skin Substitutes market is driven by several factors, including rising incidence of burns and chronic wounds, advancements in tissue engineering, and increasing demand for better wound care solutions. Innovations like bioengineered scaffolds, growth factor-infused substitutes, and improved integration with natural tissues have expanded their applications across healthcare. The focus on improving patient outcomes, reducing recovery times, and minimizing hospital stays has further fueled demand, as tissue engineered skin substitutes offer critical benefits in wound management. Additionally, growing healthcare spending, rising awareness of advanced wound care treatments, and increased investment in regenerative medicine have contributed to market growth, encouraging the adoption of tissue engineered skin substitutes in diverse medical settings.

SCOPE OF STUDY:

The report analyzes the Tissue Engineered Skin Substitutes market in terms of US$ Thousand by the following Application; End-Use; Product, and Geographic Regions/Countries:

Segments:

Product (Biological, Synthetic, Biosynthetic); Application (Acute, Chronic); End-Use (Hospitals, Wound Care Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 33 Featured) -

  • Amarantus Bioscience Holdings, Inc.
  • BSN medical
  • ConvaTec Group PLC
  • Integra LifeSciences Corporation
  • Kerecis
  • LifeNet Health
  • Mallinckrodt
  • Medline Industries, Inc.
  • MiMedx
  • Molnlycke Health Care AB
  • Organogenesis Inc.
  • Regenicin
  • Smith & Nephew
  • Tissue Regenix

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Tissue Engineered Skin Substitutes - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Use in Burn Treatment and Wound Care Spurs Market Demand
    • Advancements in Bio-Engineered Skin Solutions Drive Market Growth
    • Increasing Adoption in Diabetic Foot Ulcer Management Expands Addressable Market
    • Rising Focus on Chronic Wound Care Strengthens Business Case
    • Focus on Reducing Surgical Recovery Time Enhances Demand
    • Increasing Use of Collagen-Based and Synthetic Skin Substitutes Expands Market Opportunities
    • Advancements in 3D Bioprinting Technologies Propel Tissue Engineering Solutions
    • Growing Emphasis on Minimally Invasive Procedures Drives Adoption
    • Rising Use of Skin Substitutes in Reconstructive Surgeries Sustains Market Growth
    • Focus on Cosmetic and Aesthetic Applications Expands Market Scope
    • Increasing Focus on Developing Off-the-Shelf Skin Substitutes Generates Opportunities
    • Growing Use in Pediatric Wound Care Propels Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tissue Engineered Skin Substitutes Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Tissue Engineered Skin Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Biological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Biological by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Synthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biosynthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Biosynthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Acute by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Acute by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Chronic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Chronic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Wound Care Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Wound Care Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: USA 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: USA 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • JAPAN
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • CHINA
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: China 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: China 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • EUROPE
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • FRANCE
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 52: France Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: France 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: France 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • GERMANY
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • ITALY
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • UNITED KINGDOM
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 71: UK 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 73: UK 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030

IV. COMPETITION